The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease

(2016) N. To et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study

(2016) D. C. Baumgart et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease

(2016) Parambir S. Dulai et al.   INFLAMMATORY BOWEL DISEASES

A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

(2015) C. A. Siegel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management

(2015) N. S. Ding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pseudomonas Meningitis During Vedolizumab Therapy for Crohn’s Disease

(2015) Brigid S. Boland et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

(2015) Glen S. Hazlewood et al.   GASTROENTEROLOGY

Assessment of mucosal healing in inflammatory bowel disease: review

(2015) Parambir S. Dulai et al.   GASTROINTESTINAL ENDOSCOPY

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients

(2015) Edward Shelton et al.   INFLAMMATORY BOWEL DISEASES

Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice

(2015) Emily E. Vivio et al.   Journal of Crohns & Colitis

Risks of Serious Infection or Lymphoma With Anti–Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic Review

(2014) Parambir S. Dulai et al.   Clinical Gastroenterology and Hepatology

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases

(2014) Silvio Danese et al.   GASTROENTEROLOGY

The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease

(2014) Parambir S. Dulai et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD

(2014) Parambir S Dulai et al.   GUT

Comparative Efficacy of Biologic Therapy in Biologic-Naïve Patients With Crohn Disease: A Systematic Review and Network Meta-analysis

(2014) Siddharth Singh et al.   MAYO CLINIC PROCEEDINGS

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease

(2013) Jean–Frédéric Colombel et al.   Clinical Gastroenterology and Hepatology

The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis

(2013) Brian G. Feagan et al.   GASTROENTEROLOGY

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

(2013) Laurent Peyrin-Biroulet et al.   GUT

Effect of Tumor Necrosis Factor-α Blockade on Mucosal Addressin Cell-adhesion Molecule-1 in Crohnʼs Disease

(2013) Paolo Biancheri et al.   INFLAMMATORY BOWEL DISEASES

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease

(2012) S. Schreiber et al.   Journal of Crohns & Colitis

Current smoking differentially affects blood mononuclear cells from patients with crohnʼs disease and ulcerative colitis: Relevance to its adverse role in the disease

(2011) Vivianne Bergeron et al.   INFLAMMATORY BOWEL DISEASES

Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: Biological roles and effects of TNF and TNF antagonists

(2010) Yehuda Chowers et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE